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S6 kinase 2 (S6K2) is a member of the AGC kinases super-family. Its closest homolog,
S6K1, has been extensively studied along the years. However, due to the belief in the
community that the high degree of identity between these two isoforms would translate
in essentially identical biological functions, S6K2 has been largely neglected. Neverthe-
less, recent research has clearly highlighted that these two proteins significantly differ in
their roles in vitro as well as in vivo. These findings are significant to our understanding
of S6 kinase signaling and the development of therapeutic strategies for several diseases
including cancer. Here, we will focus on S6K2 and review the protein–protein interactions
and specific substrates that determine the selective functions of this kinase.
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INTRODUCTION
The ribosomal protein S6 kinases constitute a super-family of pro-
teins initially discovered based on their ability to phosphorylate a
40S ribosomal subunit component, the ribosomal S6 protein. The
p90 ribosomal S6 kinases (RSKs), comprising RSK1–4 (1), were
first identified followed by the p70 ribosomal S6 kinase, S6K1 (2,
3). It took an additional 10 years for the p70 ribosomal S6 kinase
homolog, S6K2, to be discovered (4–6). The high degree of homol-
ogy between S6K1 and S6K2 has for many years led researchers to
assume that these were redundant kinases with essentially over-
lapping functions. This introduced a bias toward S6K1-oriented
research, as this isoform came to be considered the prototypical
S6K. However, more recent research clearly indicates that these two
isoforms also have distinct biological functions the understand-
ing of which may have implications for therapeutic intervention.
Therefore,while other publications exist that review S6Ks and their
upstream pathways (7, 8), here we will focus specifically on S6K2
and highlight the distinct biological function of this isoform.
STRUCTURE OF S6K2
Human S6K2 is encoded by the 15 exons of the RPS6KB2
gene on chromosome 11 (11q13). The S6K2 mRNA (ID
ENST00000312629) gives rise to two protein products through
the use of alternative translational start sites: a long form (p56
S6K2) and a short form (p54 S6K2) that differ by the presence
or absence of an N-terminal 13 amino acid segment. The overall
structure of S6K2 is very close to that of S6K1 (Figure 1A). The
kinase domain of S6K2 shares 83% amino acid identity with that
of S6K1, a fact that has long justified the lack of interest in finding
isoform-specific substrates for these proteins. The kinase domain
is followed toward the C-terminus by a kinase extension domain
and a pseudo-substrate inhibitory region. The greatest degree of
divergence between S6K1 and S6K2 lies in the C-and N-terminus, a
fact that has enabled the development of S6K2-specific antibodies
(9). The presence in the C-terminus of S6K2 of a nuclear local-
ization sequence (NLS) means that this isoform is predominantly
localized to the nuclei of quiescent cells (10). In addition, the long
form of S6K2 contains in its 13 amino acid extension an additional
putative NLS. This results in the different cellular distribution of
these two isoforms as the two NLS motifs in p56 S6K2 confers
constitutive nuclear localization to this variant, while p54 S6K2
shuttles between the nucleus and the cytoplasm in response to
growth factor signaling. The C-terminus of S6K2 also contains a
proline-rich region which has been proposed to promote interac-
tion with SH3 and WW domains putatively present in its binding
partners (4). While shorter isoforms of S6K1 have been shown to
be generated by alternate mRNA splicing (11), no such variants
have yet been reported for S6K2. However, the high degree of con-
servation between the two proteins raises the possibility that simi-
lar regulation may take place for the RPS6KB2 gene. Indeed, eight
transcripts have been reported for S6K2 with a corresponding pro-
tein found for only one (ID ENST00000312629) of the four protein
coding transcripts (ID ENST00000539188, ENST00000524934,
ENST00000524814, ENST00000312629). This may have impor-
tant functional consequences as, unlike its full length counterpart,
an S6K1 splice variant, p31S6K1, was shown to have oncogenic
potential (12).
S6K2 ACTIVATION AND POST-TRANSLATIONAL
MODIFICATION
S6K2 ACTIVATION
Many of the residues that are required for kinase activation are
common between S6K1 and S6K2 as seven of the eight ser-
ine/threonine phosphorylation sites present on S6K1 are con-
served in S6K2 (Thr-228, Ser-370, Thr-388, Ser-403, Ser-410,
Ser-417, and Ser-423 on p54 S6K2) (4, 6, 10) (Figure 1A). The
activation of S6K2 occurs in a step-wise manner (Figure 1B).
An initial barrier to overcome is the repression exerted by the
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FIGURE 1 | Structure and activation of S6K2. (A) Domain organization of
S6K2, post-translational modifications together with involved enzymes, and
percentage homology with S6K1. Nuclear localizations sequences (NLS);
N-terminal regulatory region (NR); kinase domain (KD); kinase extension
region (KE); C-terminal regulatory region (CR); pseudo-substrate domain (PS);
turn motif (TM); hydrophobic motif (HM); pseudo-substrate region (PS);
phosphorylation (P), ubiquitination (Ub); acetylation (Ac). (B) Step-wise model
of activation of S6K2.
C-terminal autoinhibitory pseudo-substrate domain. This is dealt
with by phosphorylation of the three proline-directed serines in
the autoinhibitory domain, Ser-410, Ser-417, and Ser-423 down-
stream of MEK/ERK signaling. We and others have found this first
step to be crucial for S6K2 activation in various cell types (13, 14),
as this domain exerts a far more repressive role on S6K2 activity
than it’s equivalent for S6K1 (15, 16). This event is presumed to
open the kinase conformation, exposing additional phosphoryla-
tion sites to activating kinases. In agreement with this, deletion
of the autoinhibitory region increases basal activity of S6K2 and
sensitizes the kinase to activation by various agonists (15). Subse-
quent phosphorylation of Ser-370 then enables phosphorylation
of Thr-388 by the mTORC1 complex followed by that of Thr-228
by PDK1 (17). The T388 site lies within a conserved sequence of
the kinase extension domain (F-X-X-F/Y-S/T-F/Y) known as the
hydrophobic motif, a region found in many AGC kinases. Phos-
phorylation of this site by mTOR is achieved following the binding
of the mTORC1 complex component Raptor to the TOR signaling
(TOS) motif present in both S6K1 and 2 (18, 19). Interestingly,
despite the conservation of the hydrophobic motif, substitution
of Thr-388 by a glutamic acid (T388E) renders S6K2, but not
S6K1, constitutively active. However, phosphorylation of both the
Ser-370 and Thr-228 is crucial for S6K2 activity. Indeed, sub-
stitution of the latter site for alanine renders the T388E mutant
inactive while that of the first prevents Thr-388 phosphorylation.
As S6K2 is mainly a nuclear protein and mTOR shuttles between
the cytoplasm and the nucleus, it was shown that S6K2 activity
was increased by targeting mTOR expression to the nucleus (20).
Despite S6K1 and S6K2 both lying downstream of mTOR
(Figure 2), there is evidence to indicate that they may be regulated
through different pools of this upstream kinase. Indeed, both S6K
isoforms react differently to nutrient deprivation, a known modu-
lator of mTOR activity. For instance inhibition of protein synthesis
by leucine deprivation in myotubes, results in dephosphorylation
of S6K1, without affecting S6K2 activity (21). The existence of two
separate pools of mTOR regulating the two S6K isoforms is further
suggested by the differential sensitivity of S6K1 and 2 kinase activ-
ity to the mTOR inhibitor, rapamycin. Indeed, the involvement
of mTORC1 in the activation of S6K2, led several researchers to
report the sensitivity of S6K2 to this inhibitor (14, 17, 22). How-
ever, the majority of reports suggesting equivalent sensitivity of
S6K1 and 2 to rapamycin used concentrations of this drug that
non-selectively inhibit the MEK/ERK pathway, therefore indirectly
targeting S6K2 independently of its effect on mTOR (13). Hence,
when used at the minimal concentrations that fully inhibit S6K1
activity, rapamycin often fails to significantly alter S6K2 activ-
ity in several cell systems [(13) and unpublished data from our
lab]. These findings are consistent with the reported existence of a
rapamycin-resistant mTORC1 activity pool (23, 24) that can effi-
ciently be targeted by mTOR ATP-competitive inhibitors (23, 25).
ADDITIONAL PHOSPHORYLATION EVENTS
While expression of an mTOR variant targeted to the nucleus
increases activation of S6K2, nuclear localization of S6K2 is not
indispensable for activation of this kinase. Indeed, S6K2, but not
S6K1, is phosphorylated in vitro as well as in vivo by protein
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FIGURE 2 | Signaling pathways upstream and downstream of S6K2 that regulate its activation, localization, expression, and functions.
kinase C (PKC) (26). The site of phosphorylation was identified
as S486 in p54 S6K2 (S486 in p56 S6K2), located within the C-
terminal NLS. While phosphorylation of this site did not affect
the activity of S6K2, it impaired the function of the NLS leading
to cytoplasmic accumulation of the kinase upon cell stimulation
with PKC agonists such as PMA. In contrast, S6K1 sub-cellular
localization was not modulated by this treatment, highlighting
a specific mechanism regulating S6K2 nucleo-cytoplasmic shut-
tling. All PKC isoforms were capable of phosphorylating S6K2,
with PKCδ appearing to be the most efficient in vitro. However,
this specificity seemed to disappear in vivo with all PKCs being
equally potent.
In addition to being serine/threonine phosphorylated, S6K2,
as well as S6K1, can be tyrosine phosphorylated downstream of
receptor tyrosine kinase activation (27). Both S6Ks were found to
associate with the PDGFR, HGFR, and CSFR. Upon stimulation
of these receptors, N-terminal tyrosine phosphorylation of S6Ks
occurred (Y39 on S6K1 and Y45 on S6K2) in a SRC-dependent
manner. This event did not result in modulation of S6Ks activity
or the gross redistribution of these enzymes, although a fraction of
S6K1 was found to relocates to membrane ruffles where the acti-
vated RTKs are expected to reside. Although this pathway seems
shared between S6K1 and 2, it is worth noting that while SRC
family members were equally able to phosphorylate both iso-
forms in vitro, S6K2, but not S6K1, was tyrosine phosphorylated
in response to FYN transgene expression in vivo. This may reflect
differential wiring of these isoforms to the SRC family members
through alternate cellular multi-protein complexes.
In addition to phosphorylation events, S6K2 is also the target
of ubiquitination (28, 29) and of acetylation on a lysine residue
close to the C-terminal PDZ binding motif (30). The latter mod-
ification does not impact on S6K2 kinase activity or sub-cellular
localization but increases the stability of this kinase (see Control
of S6K2 Steady-State Levels).
CELLULAR EXPRESSION AND LOCALIZATION OF S6K2
CONTROL OF S6K2 STEADY-STATE LEVELS
There is currently little to no information on the transcriptional
or translational regulation of S6K2 expression. However, much
more is known about the regulation of S6K2 stability. Steady-state
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levels of S6K2 and 1 are regulated through the opposing effects
of ubiquitination and acetylation. Indeed, degradation of S6K1
and S6K2 is mediated by ubiquitination followed by proteosomal
degradation (28, 29). This is promoted by growth factor signaling
in cell lines although independently of phosphorylation/activation
of these kinases. Conversely, cell stress, such as that induced by UV
exposure, stabilizes both proteins. However, unlike for S6K1, the
molecular pathway regulating S6K2 ubiquitination is currently
unknown. Indeed, while the ROC1 ubiquitin ligase was shown to
specifically interact and ubiquitinate S6K1 (31), the corresponding
partner for S6K2 has not yet been identified. S6K1/2 degrada-
tion is counteracted by the stabilization of this protein through
a C-terminal lysine acetylation event. This occurs through inter-
action with the acetyltransferases p300 and p300/CBP-associated
factor (PCAF) (Figure 2). Hence, overexpression of p300 or inhi-
bition of deacetylases leads to an increase in the levels of both
kinases (30). Interestingly, overexpression of p300 has been linked
to decreased overall survival in patients suffering from a wide
variety of malignancies (32–36) while that of PCAF has been asso-
ciated with drug resistance (37–39). However, the role of S6K2 in
these backgrounds still remains to be established. S6K1 seems to be
targeted by both HDAC and sirtuins for de-acetylation, but S6K2
seems entirely dependent on HDAC showing differential regula-
tion of these isoforms. The involvement of HDACs in this process
may provide a further link between these kinases and the transcrip-
tional machinery (see Regulation of Transcription). Moreover, the
stabilization of S6K2 by acetylation together with the pro-survival
and drug resistance phenotypes associated with overexpression of
this kinase (see Control of Cell Survival) may hinder the efficiency
of HDAC inhibitors in the clinic.
SUB-CELLULAR LOCALIZATION OF S6K2
As mentioned above, S6K2 mainly resides in the nucleus of resting
cells. Closer examination reveals that it is the long form of S6K2
that is predominantly nuclear by virtue of its two NLSs. In con-
trast, the short form of S6K2 shuttles between the nucleus and the
cytoplasm in response to growth factor signaling. In addition to its
diffuse nuclear localization, a proportion of S6K2, but not S6K1,
has been shown to co-localize with CTR453 and γ-tubulin at the
level of the centrosome. This localization, demonstrated in multi-
ple cell lines using both immunofluorescence and immunoblotting
of purified centrosome (40), was stable throughout the cell cycle.
Finally, cytoplasmic S6K2 has been shown to have a speckled distri-
bution (40), although the structural components of these speckles
remains undetermined.
TISSUE EXPRESSION OF S6K2 IN HEALTH AND DISEASE
PHYSIOLOGICAL EXPRESSION OF S6K2
S6K2 is expressed at various levels in different mouse and human
tissues, and its expression levels often inversely correlate with those
of S6K1 (41). In Humans, S6K2 expression was found in all tissues
with the exception of the neuropil, the peripheral nervous sys-
tem, and adipocytes. However, expression levels between organs
vary considerably, with highest levels found in the gastrointesti-
nal tract, the central nervous system and the lung. In contrast,
most mesenchymal cells stain weakly for S6K2. Although S6K2 is
detected in normal tissues, its expression levels are often very low
compared to those found in corresponding tumor samples [(42)
and see S6K2 Protein Levels in Cancer and Normal Corresponding
Tissues].
EXPRESSION OF S6K2 IN CANCER AND ITS SIGNIFICANCE
S6K2 protein levels in cancer and normal corresponding tissues
S6K2 has been shown to be expressed in the overwhelming major-
ity (88%) of cancer samples investigated and the level for this
kinase compared between several cancer types and corresponding
normal tissue. These studies demonstrated that normal tissue usu-
ally express low levels of this kinase as compared to those found in
tumor samples (42–45) and that overexpression of S6K2 was more
common than that of S6K1 (e.g., 80 versus 25% in breast and 18
versus 8% for endometrial cancer). In addition to changes in the
levels of expression of S6K2, investigators also identified changes
in the sub-cellular localization of this kinase between normal and
malignant tissues. For instance, Filonenko et al. demonstrated
that nuclear accumulation of S6K2 was a distinguishing feature
of breast cancer cell in situ, whereas this kinase was only found
in the cytoplasm of normal breast cells (43). Moreover, presence
of S6K2 in the nucleus positively correlated with proliferating cell
nuclear antigen (PCNA) and Ki-67 staining in breast cancer tis-
sues, demonstrating a link between the presence of S6K2 in this
compartment and cell proliferation (46). It is noteworthy that no
such correlation existed in the case of S6K1. Interestingly, nuclear
localization of S6K2 was further increased in cells localized at the
periphery of the tumor where tumor cells are in contact with
healthy tissue. Hence, it is tempting to speculate that the nuclear
activity of S6K2 is somehow promoting tumorigenesis. The role of
S6K2 in tumorigenesis is further suggested by the fact that expres-
sion levels of S6K2 in various tissues seem to influence the role of
S6K1 in mediating PTEN haplo-insufficiency-driven tumorigenic-
ity. Indeed, S6K1 downregulation impaired tumor development
downstream of mTORC1 hyperactivation in Pten± mice only in
tissues where S6K2 expression levels were low (41). Furthermore,
in endometrial cancer, increased nuclear localization of S6K2 cor-
related with tumor grade (44), while in lung cancer, increased
expression of S6K2 correlated with drug resistance (42). This
would further suggest that S6K2 expression is linked to cancer
progression.
Interestingly, phosphorylation of the ribosomal S6 protein was
shown not to correlate with expression levels of either S6K1 or
S6K2 in endometrial and breast cancer (43, 44). This lack of cor-
relation is in contradiction with the results obtained from animal
models showing that S6K2 knockout mice, unlike their S6K1 coun-
terpart, showed a dramatic reduction in the cellular levels of S6
phosphorylation (47). Hence, the lack of correlation found in tis-
sue samples may be an artifact generated by the modalities of
tissue processing or the saturation of these phosphorylation events
beyond a certain threshold of S6K expression. However, conclu-
sions on this issue are further complicated by results obtained
in knock-in mice where the five phosphorylation sites in S6 are
replaced by alanine residues. Indeed, these animals show a pheno-
typic overlap with that of S6K1−/− mice including a cell growth
defect associated with reduction in cell size (48). This is somehow
surprising considering the lack of impact on S6 phosphorylation
of knocking out S6K1 and the previously mentioned privileged
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link between S6K2 and S6 phosphorylation in mice (47), a find-
ing that our lab corroborated in human cell lines using an siRNA
approach (42). However, some reports suggest that reliance of S6
phosphorylation on one or the other S6K isoform may depend on
the nature of the mitogen stimulation (49). Also, these discrep-
ancies may be explained by date failure to take into account the
sub-cellular localizations of S6K1, S6K2, and S6, variables that may
impact considerably on the overall phosphorylation of the latter
protein. The change in sub-cellular distribution of S6K2 observed
between tumor and healthy tissues would support this hypothesis
(43, 44). Finally, it may be postulated that increased expression of
S6K1 and S6K2 does not correlate with increased activity of these
kinases.
Amplification of S6K2 in cancer
Amplification of the chromosomal region 11q13 where the S6K2
resides is found in 15–20% of breast cancers samples studied, an
event implicated in resistance to endocrine therapy (50). Ampli-
fication of S6K2 among these samples correlated with increased
mRNA levels for this kinase, ER positive status and worse prog-
nosis (45). However, S6K2 copy number gain and nuclear local-
ization of the protein was related to an improved benefit from
tamoxifen among patients with ER+/PgR+ tumors, while in the
ER+/PgR− subgroup, nuclear S6K2 rather indicated decreased
tamoxifen responsiveness. The presence of the S6K2 amplicon
correlated significantly with amplification of the 8p12 region, con-
taining the FGFR1, PPAPDC1B, and 4EBP1 genes (50). This latter
amplification was associated with increased mRNA levels for all
three genes. Of the genes present in the proximal 11q13 region,
S6K2 expression alone correlated with that of FGFR1,PPAPDC1B,
and 4EBP1. Using univariate analysis, it was found that 8p12
gain/amplification was significantly associated with increased risk
of distant recurrence among patients with 11q13 positive tumors.
This analysis could be further refined to demonstrate that high
level of FGFR1 and 4EBP1 mRNA expression alone predicted a
worse outcome in this patient group. Although co-expression of
FGFR1 and S6K2 would be logical in view of the link between
FGF2-mediated survival and downstream S6K2 activity (42), an
associated increased expression of 4EBP1, a reported tumor sup-
pressor, may seem surprising. However, phosphorylated 4EBP1
has been suggested to stimulate mTORC1 activity (51), a process
that would in turn increase S6K2 activation. In addition to the case
of breast cancer, S6K2, but not S6K1, was found amplified in about
5% of gastric carcinoma patient samples (52). This amplification
was associated with a significance decrease in the overall survival
of patients with advanced disease.
S6K2 variants and disease
One of the neuropathological hallmarks in Alzheimer’s disease
(AD) is the neurofibrillary tangles formed by hyperphosphory-
lated microtubule-associated Tau protein. Vazquez-Higuera et al.
investigated genetic variations in a set of 20 candidates kinases
involved in tau phosphorylation at sites correlating with AD (53).
They reported that the distribution of the minor allele frequencies
for these kinases did not differ significantly between sufferers and
control groups, except for S6K2 where variations in intron 2 was
increased in patients (50%) versus controls (39%). In addition
to correlating with increased risks of developing the disease, this
minor allele was also associated with late onset of AD. Genetic
variations in the S6K2 gene have also been linked to the risk of
developing colon cancer where they are found in tumors with
SNPs inPIK3CA,CIMP positivity,and mutated KRAS2 (54). While
CIMP positivity in colon cancer generally correlates with poor
tumor differentiation and patient prognosis (55, 56), it was also
shown to independently predict the survival benefit from 5-FU
chemotherapy (57, 58). Hence, the polymorphism in S6K2, and
its pathway associations, may have prognostic value and therapeu-
tic significance. However, the true impact of these SNPs to S6K2
biological activity is yet to be experimentally confirmed.
BIOLOGICAL FUNCTIONS OF S6K2
MOUSE MODELS OF S6K2 REVEAL LITTLE OF ITS BIOLOGICAL
FUNCTIONS
Knockout mice for S6K1 and S6K2, in isolation and combination,
have been bred (47). Single-knockout animals were viable and
born at the expected Mendelian ratio. S6K1−/− mice were signif-
icantly smaller than their wild-type counterpart while S6K2−/−
animals tended to be slightly larger. The latter change is thought
to result from compensatory mechanisms whereby S6K2 knockout
leads to increased S6K1 activity. This possibility is independently
supported by cell line-based experiments in which RNAi-mediated
silencing or inhibition of S6K2 leads to increased baseline S6K1
activity (13, 42). Taken together, these data provide confirma-
tion for the proposed role of S6K1 in the control of cell size
in mammalian cell lines (59). Conversely, S6K1 knockout mice
presented with increased S6K2 mRNA levels in all organs tested,
a fact that may explain the observed physiological inverse cor-
relation between the tissue expression for S6K1 and S6K2 (see
Physiological Expression of S6K2). In contrast to single-knockout
animals, mice lacking both S6K1 and S6K2 suffered from perina-
tal lethality. This was not due to defects in cell cycle progression
or 5′-TOP mRNAs translation in these animals. Also, analysis of
embryos at 18.5 days of gestation indicated normal Mendelian
distribution. Instead, one third of the double-knockout animals
were born dead and the majority of those born alive developed
signs of cyanosis leading to death shortly after birth. The minor-
ity of mice surviving past the first few days following delivery
succeeded in reaching adulthood with similar growth rates as the
S6K1−/− animals and were fertile. Histopathological analysis per-
formed to understand the reason for perinatal lethality amongst
the double-knockout litters revealed no gross anatomical abnor-
malities. However non-viable animals showed hyperemic internal
organs, occasional dilated heart chambers as well as several hem-
orrhagic sites. In short, none of the phenotypes observed in these
animal models could be attributed to some distinct role of S6K2
and further biochemical analysis was required before biological
functions of this kinase started to transpire.
REGULATION OF TRANSCRIPTION
Genome-wide microarray experiments revealed that S6K1 and 2
regulate the general transcriptional program. Indeed, 456 mRNAs
were downregulated in the whole-cell extracts from starved
S6K1/S6K2 double-knockout mice livers as compared to that of
wild-type controls following re-feeding (60). Specifically, S6K2,
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but not S6K1, has been shown to directly interact in a mitogen-
inducible fashion with the general transcription factor Yin Yang
1(YY1), an association that required the C-terminal region of
S6K2 (61). YY1 has been involved in a wide range of biolog-
ical processes through the recruitment of general components
of the transcriptional machinery such as RNA polymerase II,
ATF and SP1 as well as various transcriptional co-activators and
co-repressors including DNA methyltransferases (DNMTs), his-
tone acetyl transferases (p300, CBP, PCAF), histone deacetylases
(HDAC 4), protein arginine methyltransferases (PRMTs), histone-
lysine N -methyltransferase (Ezh1/2), Sumo-conjugating enzyme
(Ubc9), and ubiquitin ligases (Mdm2). The function of YY1 is
regulated by post-translational modifications including phospho-
rylation, sumoylation, acetylation, and ubiquitination so it is pos-
sible that interaction with S6K2 results in the phosphorylation
and regulation of transcriptional activity of this protein. S6K2,
along with S6K1, has also been involved in the transcription of
ribosomal proteins (60). Indeed, analysis of the ribosome bio-
genesis transcriptional program after feeding in liver cells from
S6K1−/−/S6K2−/− mice showed that over 75 factors involved
in ribosome biogenesis were controlled by S6Ks. Importantly,
these changes were also observed in knock-in mice for a non-
phosphorylatable mutant of rpS6. However, this was not associated
with changes in the recruitment of RNAs into polysomes, revealing
a role for S6Ks in the regulation of transcription that is dissociated
from the translational program. Interestingly, S6K1 and 2 were
functionally redundant in this biological process as overexpres-
sion of either isoform into the double-knockout cells rescued the
phenotype.
The regulation of transcription by S6K2 also plays an important
role in immune cells differentiation. Indeed, the import into the
nucleus of RORγ, a critical transcription factor for the differentia-
tion of a sub-class of IL-17-secreting CD4+ T-helper lymphocytes,
is dependent on the binding of this protein to S6K2 (Figure 2) (62).
This occurs because RORγ, a protein that lacks an NLS, uses S6K2
to piggyback its ways into the nucleus. The interaction of S6K2
with RORγ was resistant to rapamycin treatment. However, the
import of RORγ into the nucleus was rapamycin-sensitive, sug-
gesting a role for mTORC1 in S6K2-mediated nuclear import of
RORγ.
REGULATION OF PROTEIN TRANSLATION
S6K2, like S6K1, appear not to be involved in the general pro-
tein translation program. Indeed, despite the impairment in S6
phosphorylation found in cells from S6K1/2 double-knockout
mice, translation of 5′-TOP mRNAs were still promoted by mito-
gen stimulation (47). This and other data (63, 64) indicated that
S6 phosphorylation is dispensable for this process., Furthermore,
these results demonstrated that other kinases lying downstream
of the MAPK pathway substituted for S6K1 and S6K2 in phos-
phorylating two serine sites (235 and 236) on S6 in response to
mitogen stimuli. This role has since been attributed to members
of the RSK family. However, unlike RSKs, S6Ks are capable of cat-
alyzing the ordered phosphorylation of the five sites present in the
C-terminus of the S6 protein (S236, S235, S240, S244, S247) (65),
although the physiological significance of these events still remains
unclear (66). While it is clear that S6K2 does not play a major role
in the cap-dependent translation of housekeeping proteins, this
kinase is involved in the cap-independent translation of selective
mRNAs (Figure 2). These, including the Bcl-XL, MCL1, and XIAP
mRNAs, may be selected for regulation by S6K2 through the pres-
ence in their 5′UTR of an internal ribosome entry site (IRES) (67,
68), the activity of which S6K2 controls through the phosphoryla-
tion of IRES transactivating factors (ITAFs) such as PDCD4 (69)
(see Control of Cell Survival).
CELL CYCLE REGULATION
S6K2 has been suggested to play a role in mitosis, as a pool of
this kinase localizes at the centrosome and S6K2 activity peaks at
the G2 and M phases of the cell cycle (70). However, it is worth
noting that neither MEFs from S6K1/S6K2 double-knockout mice
nor their corresponding embryonic stem cells show significant
defects in cell proliferation or cell cycle distribution (47). Hence,
the role of S6K2 in the cell cycle may be context dependent and
limited to situations where mitogenic stimulus is applied or com-
pensatory mechanisms are not available. Indeed, in IL3-dependent
immortalized murine bone marrow-derived pro-B-cells and pri-
mary mast cells, IL3 stimulation activated S6K2,which contributed
to the mitogenic effect of this growth factor (71). In these cells,
S6K2 activity was able to shorten the G1 phase of the cell cycle,
enabling cells to enter the S-phase at an increased rate. However,
S6K2 activity alone was not able to substitute the need for IL3, as
cells expressing a kinase-active S6K2 in the absence of IL3 failed to
proliferate. This suggests that S6K2 is only playing a facilitating role
in this process, a finding that may help explain the non-essential
role of this kinase for cell cycle progression in animal models. It
is worth noting that our recent collaborative research has high-
lighted specific S6K2 partners that mediate the effect of this kinase
on the cell cycle. We showed that S6K2 binds several heterogenous
ribonuclear proteins (hnRNPs) in a mitogen-inducible manner.
One such RNP, hnRNPF was required for cell proliferation driven
by S6K2 (72). Indeed, silencing of hnRNPF thwarted the prolifer-
ative effects of S6K2 while overexpression of this RNP increased
cell proliferation in a rapamycin-sensitive manner. Consistent with
the latter result, mitogen stimulation led to the recruitment of
preformed S6K2-hnRNPF complexes to mTORC1.
The contradictory findings published on the role of S6K2 in the
regulation of the cell cycle may also be explained by the extensive
rewiring of signaling pathways occurring during tumorigenesis
together with accompanying overexpression of S6K2. These may
significantly change the contribution of this kinase to the promo-
tion of mitosis, a possibility supported by the correlation between
Ki-67 staining, a marker for cell proliferation, and S6K2 overex-
pression found in tumor samples (44). In addition, the increased
nuclear localization of S6K2 in cancer (43, 44) may also impact
on its pro-mitotic function. A possible increased involvement of
S6K2 in the regulation of cell cycle in malignant tumors as com-
pared to normal tissue could provide a therapeutic window for the
targeting of this kinase in the treatment of cancer patients.
CONTROL OF CELL SURVIVAL
The role of S6K2 in the regulation of apoptotic cell death was first
demonstrated by research from our lab (42). The serum levels for
basic fibroblast growth factor (FGF2) are often elevated in patients
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with a variety of malignancies and are a poor prognostic factor on
uni- and multi-variate analysis (73–78). We found that treatment
of lung cancer cells with FGF2, used at concentrations commonly
found in the serum of carcinoma patients, promoted cell sur-
vival, and drug resistance through translational up-regulation of
anti-apoptotic proteins such as Bcl-XL and XIAP (79, 80). The
mRNAs for these proteins are characterized by the presence in their
5′UTR of an IRES, a three-dimensional structure that represses
the efficiency of their translation. Hence, increased expression of
these proteins requires the unwinding of these structures and the
recruitment of ITAFs that de-represses their translation. Investiga-
tion into the signaling involved in this response revealed that S6K2,
but not S6K1, was required for the increased translation of these
anti-apoptotic proteins in the absence of de novo mRNA synthesis
(42, 80). In support of this, silencing of S6K2 using siRNAs pre-
vented FGF2-induced drug resistance as well as up-regulation of
Bcl-XL and XIAP. Moreover, in un-stimulated cells, S6K2 down-
regulation was accompanied by a decrease in the steady-state
levels of both anti-apoptotic proteins, suggesting that this kinase
is not only involved in promoting their production downstream
of pro-survival signaling but also participates to their baseline
translation. In contrast, silencing S6K1 had no impact on either
protein whether in the presence or absence of mitogen stimulation.
Conversely, overexpression of a kinase-active mutant for S6K2, but
not S6K1, increased the translation of Bcl-XL and XIAP, promoted
baseline cell survival and induced drug resistance in the absence of
FGF2 stimulation (42). The anti-apoptotic function of S6K2 was
dependent on the FGF2-inducible formation of a multi-protein
complex comprising S6K2, BRAF, and PKCε (Figure 2). Indeed,
disruption of this complex through the silencing of BRAF or PKCε
prevented the pro-survival activity of S6K2. The composition of
this multi-protein interaction was selective as it did not include
other PKC or RAF isoforms. Similarly, S6K1 was unable to form
a complex with these S6K2 partners. Tandem affinity purification
using S6K2 as bait in the presence and absence of FGF2 stimu-
lation in HEK93 cells enabled the identification of downstream
mediators that regulate the translation of S6K2’s anti-apoptotic
targets. One such interactor, the tumor suppressor programed cell
death 4 (PDCD4) that normally binds to the IRES of Bcl-XL and
XIAP to repress their translation, is phosphorylated by S6K2 (69).
This post-translational modification leads to the degradation of
PDCD4 and subsequent derepression of Bcl-XL and XIAP transla-
tion. It is also noteworthy that hnRNPF and hnRNPH, two ribonu-
cleoproteins previously found to regulate the differential splicing
of BCL-X into the anti-apoptotic protein BCL-XL or the pro-
apoptotic proteins Bcl-XS (81) were found to associate with S6K2
in a mitogen-inducible manner (72). Hence, in addition to being
able to regulate the translation of this protein, S6K2 may also be
able to promote the preferential splicing of BCL-X toward BcL-XL.
Further work in U2OS osteosarcoma cells demonstrated that
the Janus kinase TYK2 participated to the initially identified
S6K2/BRAF/PKCε complex downstream of FGF2 signaling (82).
In this cell system, TYK2 was required for the induction of the
anti-apoptotic proteins BCL2 and MCL1 and for the promotion
of cell survival in response to this growth factor. Whether this
finding extends to lung, or other, cancer cells in which FGF2
signaling is relevant to the development of chemoresistance is at
this point unknown. However, it suggests that inhibition of TYK2
may represent a new therapeutic strategy to target drug resistance
downstream of FGF2 signaling.
The role of S6K2 in the control of cell survival may extend
to neurodegenerative disorders. Frontotemporal dementia (FTD)
is a form of pre-senile dementia associated with focal atrophy of
the frontal or temporal lobes accompanied by deficits in cogni-
tion, behavior, and language. Mutations in progranulin (PGRN),
a protein involved in cell growth and survival (83–85), are a com-
mon cause of FTD (86). Human neurons obtained from FTD
patients with mutant PGRN were shown to have reduced cell via-
bility that correlated with a downregulation of S6K2 transcription
(87). All these changes were rescued by expression of wild-type
PGRN, directly linking this factor with expression of S6K2. This
link may have far wider relevance as serum levels of PGRN are a
clinically significant predictive marker for recurrence in patients
with HR-positive breast cancer during adjuvant tamoxifen therapy
(88). Also, high PGRN expression levels correlate with an aggres-
sive phenotype in cancer cell lines and clinical specimens from
gliomas, breast, ovarian, and renal cancers (83). However, the link
between PGRN and S6K2 in these settings is yet to be established.
S6K2 AND COGNITION
Behavioral analysis of S6K knockout mice highlighted non-
overlapping cognitive functions for S6K1 and 2. S6K1 and S6K2-
deficient mice were tested for contextual fear memory, conditioned
taste aversion, Morris water maze acquisition, exploratory behav-
ior, and long-term potentiation (89). Deficit in individual S6K
isoforms resulted in distinct patterns of behavioral modifications
with S6K1 being associated with the most pronounced phenotype.
While both isoforms participated to contextual fear memory, con-
ditioned taste aversion, and early-phase long-term potentiation,
S6K2 deficit impacted particularly on long-term contextual fear
memory and reduced latent inhibition of conditioned taste aver-
sion. However, S6K2−/−mice displayed normal spatial learning in
the Morris water maze.
S6K2 AS A THERAPEUTIC TARGET FOR CANCER
IMPORTANT CONSIDERATIONS IN THE DESIGNS OF S6K2 TARGETING
THERAPY
Since knockout mice for S6K2 have shown that this kinase was
dispensable for normal development and homeostasis, this kinase
may represent an excellent therapeutic target for cancer. However,
several lines of evidence suggest that S6K2 targeting should be
selective and not impinge on S6K1 activity. Indeed, as indicated
above, unlike S6K2 single-knockout animals, S6K1−/−/S6K2−/−
mice displayed perinatal lethality (47), suggesting that acute inhi-
bition of both isoforms simultaneously in the absence of compen-
satory mechanisms may be deleterious to normal homeostasis.
This is confirmed by work done in Drosophila where disruption
of the unique S6K gene, dS6K, results in the death of the major-
ity of flies at the larval stage or early pupation (90). Moreover,
the S6Ks have been involved in negative feedback loops that regu-
late the PI3K and mTOR pathways. First, it was found that S6K1
and S6K2 phosphorylate IRS-1 on serine 302, a site adjacent to
its PTB domain. This phosphorylation event inhibits the binding
of IRS-1 to the insulin receptor, preventing further stimulation
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of the PI3K pathway by insulin (91, 92). Conversely, silencing of
S6K1 using siRNAs was shown to decrease IRS-1 phosphoryla-
tion on several serine residues leading to an increase in PI3K/AKT
signaling (93). In addition to targeting IRS-1, it has recently been
revealed that S6K1, but not S6K2, modulates the activation of AKT
by phosphorylating the mTORC2 complex component RICTOR
on T1135 (49, 94, 95). This phosphorylation event does not seem
to directly modulate the kinase activity of the mTORC2 com-
plex. However, expression of a phospho-deficient mutant version
of RICTOR promoted phosphorylation of AKT on S473, a site
associated with activation of this kinase (49). Hence, consider-
ing the well-documented function of AKT in tumorigenesis (96)
and the lethality of S6K double-knockout animals, a therapeu-
tic strategy targeting both S6K isoforms in cancer patient may
not be advisable. This hypothesis is further supported by results
obtained using the pan-S6K inhibitor, LYS6K2, which increases
basal and mitogen-induced AKT phosphorylation in treated cell
lines (97). Conversely, the use of rapamycin analogs to inhibit
the mTOR pathway, an approach that has been the subject of
numerous cancer clinical trials (98), would not be appropriate in
targeting the biological effects of S6K2 as some of the functions
of this kinase are resistant to this inhibitor (13, 42, 79). Hence, it
would be highly desirable to develop S6K2-specific compounds.
However, at present, no drug discovery project has attempted to
specifically target S6K2.
SMALL-MOLECULE ATP COMPETITORS
While S6K kinase inhibitors do exist, these are either pan-S6K
compounds that also target other AGC kinases [e.g., Ref. (99, 100)]
or compounds that show relative selectivity for S6K1 (101, 102).
It was initially thought that the high degree of identity between
the kinase domains of S6K1 and S6K2 would prevent the develop-
ment of S6K2-selective kinase inhibitors. However, the existence of
“selective” S6K1 inhibitors (101, 102) together with data acquired
through 3-D modeling suggest that the development of such com-
pounds would be possible. Indeed, comparison of the crystal
structure of the kinase domain of S6K1 bound to Staurosporine
(103) with the 3-D model of the same region in S6K2 reveals that
the two kinases may differ in their contact with this inhibitor. This
divergence occurs at the level of cysteine 150, a residue within the
hinge region of S6K2 and may be exploitable to tweak selectiv-
ity of pan-S6K compounds toward this isoform. In support for
this idea, the modulation of interaction of chemical compounds
with the hinge region has previously been exploited to introduce
selectivity among kinase inhibitors (104). Nevertheless, the high
level of homology between the kinase domains of AGC kinases
family members will always render the broader selectivity of these
compounds hard to secure, especially in vivo where their intra-
cellular concentration cannot be easily controlled. Hence, other
approaches for the selective inhibition of S6K2 should also be
considered.
PROTEIN–PROTEIN INTERACTION INHIBITORS
We propose that the development of protein–protein interaction
inhibitors would be a more appropriate strategy to specifically
target S6K2. Indeed, drug discovery efforts into protein–protein
interaction inhibitors have multiplied in the last few years [e.g.,
Ref. (105–109) to only cite a few] and some have already yielded
compounds that entered the clinic (105). The heightened interest
in this approach has been fueled by the relative lack of success of
small-molecule kinase inhibitors in the clinic, together with the
development of novel bioinformatics tools to predict disruption
of protein–protein interactions (110, 111). We and others have
performed co-purification of S6K2 with its interacting partners
downstream of mitogen stimulation in various cell lines [(69, 72)
and unpublished], an effort that resulted in the identification of
S6K2-specific interactors that regulate the biological functions of
this kinase (42, 69, 72). For instance, interaction of S6K2 with
BRAF and PKCε was shown to regulate the anti-apoptotic func-
tion of this kinase while that of S6K2 and hnRNPF modulated its
effect on the cell cycle. Hence, one could envision drug discovery
efforts aimed at targeting these identified interactions.
ALLOSTERIC S6K2 INHIBITORS
Two more characteristics of S6K2 may be potentially exploitable
for the development of selective compounds. The first is its C-
terminal domain which differs significantly from the same region
in S6K1 and is predicted through 3-D modeling to be fairly
unstructured and exposed. This region could be used to fish out
interacting compounds that may, through binding, alter the 3-
D conformation of S6K2. As this region also contains the NLS
for S6K2, interacting compounds may also interfere with its sub-
cellular localization. The second S6K2 characteristic is its higher
reliance for activation on the MEK/ERK-mediated derepression
from the pseudo-substrate domain. Compounds that would bind
to the kinase extension domain or hinder access to the proline-
directed phosphorylation sites may prevent S6K2 from exposing
the serine/threonine sites responsible for its activation to upstream
kinases.
CONCLUSION
It has now been 15 years since the cloning of S6K2. However, many
aspects of the regulation and biological functions of this enzyme
are still a mystery. Indeed, the high degree of homology between
S6K1 and S6K2 led us to bias most of our research toward the
first of these two isoforms, as these were thought to have identical
roles. Instead, it is now becoming clear that these enzymes have
distinct biological functions mediated by their distinct repertoires
of substrates and interactors. Our limited knowledge of S6K2 sug-
gests that this isoform may play a particularly important role in the
pathobiology of cancer and targeting this isoform could provide a
therapeutic benefit in patients. However, this will most probably
require the development of S6K2 isoform-selective compounds
that exploit its known specific protein–protein interactions and
downstream substrates that mediate its functions. The time has
come to embrace S6K2, recognize the biological diversity that this
enzyme introduces into the S6 kinase pathway and exploit this
information for new therapies.
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